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Abstract 
 
The concentration of sodium ions (Na+) is raised in solid tumours and can be measured at 
the cellular, tissue and patient levels. At the cellular level, the Na+ gradient across the 
membrane powers the transport of H+ ions and essential nutrients for normal activity. The 
maintenance of the Na+ gradient requires a large proportion of the cell’s ATP. Na+ is a major 
contributor to the osmolarity of the tumour microenvironment, which affects cell volume and 
metabolism as well as immune function. Here, we review evidence indicating that Na+ 
handling is altered in tumours, explore our current understanding of the mechanisms that 
may underlie these alterations and consider the potential consequences for cancer 
progression. Dysregulated Na+ balance in tumours may open opportunities for new imaging 
biomarkers and re-purposing of drugs for treatment. 
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Introduction 
 
The concentration of several key ions, including protons (H+) (1), potassium (K+) (2), calcium 
(Ca2+) (3) and sodium (Na+) (4) is altered in tumours. This ionic imbalance contributes to 
several cancer hallmarks, including altered growth signalling, proliferation, angiogenesis, 
invasion and metastasis (5). Just as intracellular ion concentrations can alter cancer cell 
behaviour, the extracellular “ionic tumour microenvironment” can determine how cancer, 
stromal and infiltrating immune cells behave (6). Dysregulation of ion homeostasis within the 
tumour microenvironment could therefore also contribute to tumour progression. Thus, ion 
channels and transporters, including those permeant to Na+, have potential as novel targets 
for therapeutic intervention. 
 
Control of Na+ is critical for normal cellular function and homeostatic dysregulation is a key 
feature of disease states such as acute inflammation (7) and ischaemia (8). Na+ handling is 
also altered in cancer: Na+ is raised in malignant tumours compared to corresponding 
healthy tissues (9). Tumorigenesis is accompanied by alterations to metabolism, pH 
regulation, vascularity and cell density that affect the distribution of Na+ within cancer cells 
and the extracellular tumour microenvironment. Here, we review the evidence showing that 
Na+ handling is altered in tumours, explore the mechanisms that may underlie these 
alterations and consider the potential consequences for cancer progression. We also 
highlight potential clinical applications for Na+ as a diagnostic biomarker and for targeting 
dysregulated Na+ within the ionic microenvironment of tumours alongside existing cancer 
therapeutics. 
 
The extracellular Na+ concentration ([Na+]e) is typically an order of magnitude higher (145 
mM) than intracellular [Na+] ([Na+]i; 12 mM) (10). Therefore, an increase in total tumour 
tissue [Na+] could be caused by an increase in the volume of extracellular fluid relative to the 
volume of intracellular fluid (extracellular volume fraction; Figure 1). The generation of 
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permeable vasculature in tumours by the angiogenic vascular endothelial growth factor 
(VEGF) allows leakage of plasma proteins, including glycosaminoglycans and collagen, into 
the interstitial space (11, 12). Protein leakage into the interstitium will also increase the 
colloid osmotic pressure, which contributes to the raised interstitial fluid pressure seen in 
solid tumours (13), potentially expanding the interstitial fluid volume (14, 15). Cell death 
following successful chemotherapeutic intervention would also be expected to increase the 
extracellular volume fraction. This would have implications for other ions. For example, K+ 
released into the extracellular space following tumour cell death results in an elevated 
extracellular [K+] that suppresses the anti-tumour activity of tumour infiltrating lymphocytes 
(16). Nevertheless, the increase in interstitial fluid volume may underlie the raised total 
tumour [Na+]. Although it has historically been difficult to measure accurately, there is some 
evidence that the interstitial fluid compartment is enlarged in some tumour types, including 
those which induce oedema, such as malignant gliomas and meningiomas (17-19). 
 
Raised total tumour tissue [Na+] may also be caused by increased [Na+]i, increased [Na
+]e, or 
a combination of both. Quantitative measurement of tumour [Na+]e is lacking, however, there 
is evidence that [Na+]i is raised in tumours. Early studies using x-ray dispersion 
microanalysis and flame photometry indicated that the [Na+]i of cancer cells from various 
tumour types was more than double that of cells from adjacent healthy tissues (20, 21). 
Additional approaches, including measurement of 22Na radioisotope assimilation rate by 
atomic absorbance spectrophotometry, live cell imaging using the fluorescent Na+ reporter 
SBFI-AM, and 23Na magnetic resonance imaging (23Na MRI; Box 1) have broadly confirmed 
these observations in cultured cells and cancer patients (22-27). 
 
Cellular mechanisms underlying sodium handling in tumours 
 
Numerous plasma membrane channels and transporters facilitate Na+ flux down the 
electrochemical gradient from the extracellular space into the cytosol (Table 1; Figure 2). 
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Altered expression or activity of such mechanisms in cancer cells could account for the 
raised [Na+]i observed in tumours. The ubiquitous Na
+/K+ ATPase is almost exclusively 
responsible for the removal of Na+ from cells and thus maintaining the inward gradient for 
Na+. As a result, this pump uses a significant proportion of the total ATP produced by non-
excitable cells (28, 29). Altered cellular metabolic activity may thus lead to changes in Na+/K+ 
ATPase activity. For example, when the usage of ATP for cellular proliferation is increased, 
the provision of ATP to the Na+/K+ ATPase may be reduced and, as a consequence, 
changes in [Na+]i and [Na
+]e would occur (30). Raised [Na
+]i and possibly [Na
+]e can both 
increase Na+/K+ ATPase activity to maintain Na+ homeostasis (31-33). Since this pump is so 
energetically demanding, increasing Na+ influx would increase the cellular ATP consumption 
rate. Evidence suggests that the Na+/K+ ATPase is predominantly fuelled by glycolysis in 
breast cancer cells since this delivers ATP quickly to the site where it is being used (34, 35). 
However, hypoxia has been shown to inhibit Na+/K+ ATPase activity, suggesting that 
mitochondrial ATP supply is also needed (36, 37). 
 
The inward electrochemical Na+ gradient set up by the Na+/K+ ATPase powers the activity of 
a number of different Na+-dependent transport mechanisms. The Na+/H+ exchanger (NHE) 
family is one such mechanism, which uses the inward Na+ gradient to move H+ into the 
extracellular space, thus playing a central role in pH homeostasis (38). The ubiquitously 
expressed NHE1 is activated by receptor tyrosine kinase signalling, in particular via the Ras-
extracellular signal-regulated kinase (ERK) pathway, and by osmotic stress, hormones and 
growth factors (39). NHE1 is also allosterically activated by an increase in intracellular [H+], 
as may be found in glycolytic tumour cells (40, 41). Another major pH regulation mechanism 
coupled to inward Na+ transport is the electroneutral Na+/HCO3
- cotransporter (NBCn1), 
which is upregulated in hypoxic tumours (42, 43). The imported HCO3
- neutralises H+ 
generated from high metabolic activity by forming H2O and CO2. The Na
+ gradient also 
powers the import of amino acids into cells via Na+-dependent amino acid transporters, 
many of which are overexpressed in cancers (44). Na+-dependent glucose transporters 
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(SGLTs), normally responsible for active glucose uptake in the kidney, are also functionally 
expressed in many cancers (45, 46). In addition, the Na+-K+-Cl− cotransporter (NKCC), a key 
regulator of osmotic balance and cell volume which facilitates the transport of Na+, K+ and 
2.Cl- into the cell, is also upregulated in numerous cancers (47, 48). The combined activity of 
such nutrient and electrolyte transport mechanisms is not only dependent on Na+ 
homeostasis within the tumour microenvironment, but is also predicted to raise [Na+]i, thus 
potentially contributing to the elevated Na+ signal observed in tumours. 
 
Na+ channels expressed on tumour cells also enable Na+ influx and elevation of [Na+]i. 
Voltage-gated Na+ channels (VGSCs), classically expressed in electrically excitable cells 
where they initiate action potentials via Na+ influx, are also expressed in many tumour cell 
types where they promote cancer cell invasion and metastasis (49, 50). Although the 
voltage-dependent opening of these channels is transient, they also conduct a ‘persistent’ 
inward Na+ current under resting conditions, thus providing a route for Na+ to enter the 
cytosol in non-excitable tumour cells (51-55). The amiloride-sensitive epithelial Na+ channel 
(ENaC) and the related acid-sensing ion channels (ASICs) are also Na+-selective ion 
channels which permit voltage-independent inward Na+ current. ENaC and ASICs have been 
linked to proliferation, migration, invasion and metastasis in various cancers (56, 57). Flow of 
Na+ through ENaC and ASICs is regulated by extracellular H+ (58, 59). Thus, both channels 
may contribute to elevation of [Na+]i in acidic tumours. In addition, N-methyl-D-aspartate 
(NMDA) receptors may also permit elevated [Na+]i in tumours. These ligand-gated, 
nonselective cation channels are typically expressed in the central nervous system (CNS) 
and activated by glutamate. NMDA receptors are expressed in numerous tumour types, 
including non-neuronal tumours such as pancreatic, breast and ovarian cancers, where they 
regulate invasion and correlate with poor prognosis (60-62). Proteins forming the G protein-
coupled receptor-activated Na+ leak channel (NALCN) have been suggested as potential 
cancer susceptibility loci (63), and although evidence for its involvement in cancer is limited, 
NALCN may provide an additional route for Na+ influx, thus elevating [Na+]i. Finally, the two-
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pore channel (TPC) family of lysosomal and endosomal cation channels can increase 
cytosolic Ca2+ and Na+ and have been shown to promote lung cancer cell migration (64) and 
epithelial-mesenchymal transition of breast cancer cells (65). 
 
Pathophysiological consequences of altered tumour Na+ 
 
Dysregulated Na+ handling in tumours can lead to significant physiological changes at the 
cellular level, such as altered electrical potential difference across the plasma membrane 
(membrane potential; Vm), pH, or metabolic activity. These physiological alterations can 
induce myriad effects on key tumour hallmarks from proliferative ability to invasion into 
healthy tissue and immune evasion (Figure 3). 
 
Membrane potential depolarisation 
Influx of Na+ into non-excitable cells depolarises the Vm (around 5-10 mV) (22, 66-68). In 
general, cancer cells exhibit a more depolarised Vm than their normal counterparts (around -
5 to -50 mV vs. -50 to -95 mV), which may correlate with their increased proliferative 
capacity (69). This phenomenon may be due to the changes in Vm that accompany different 
stages of the cell cycle (70). Indeed, a relatively negative Vm (Vm hyperpolarisation) can 
prevent DNA synthesis and mitosis (71). Furthermore, stem cell differentiation can only 
occur if the Vm is hyperpolarised (72). Vm depolarisation leads to reorganisation of charged 
phospholipids in the inner leaflet of the plasma membrane, which in turn enhances 
nanoclustering and activation of K-Ras promoting mitogenic signalling (73). Vm 
depolarisation is also functionally instructive in regulating cytoskeletal reorganisation, 
morphogenesis, regeneration and tumorigenesis (68, 74-78). In effect, persistent Na+ entry 
via ENaCs and VGSCs may increase proliferation, maintain a poorly differentiated 
phenotype and increase migration via depolarisation of the Vm, all aiding tumour progression. 
However, Vm depolarisation in tumour cells is likely tightly regulated given that it can also 
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promote apoptosis and isotonic volume decrease (79, 80)  and may thus present an 
interesting therapeutic target. 
 
Regulation of pH dynamics 
The extracellular microenvironment of solid tumours is commonly acidic (pH 6.5–7.2), 
whereas the intracellular pH of cancer cells is typically neutral or slightly alkaline (81, 82). 
The acidic tumour microenvironment is a critical contributory factor to many cancer hallmarks 
such as invasion, altered metabolism, drug resistance and immune evasion (83). The Na+ 
gradient across the plasma membrane impacts on pH regulation mechanisms. For example, 
an altered inward Na+ gradient will influence the pH-regulating capacity of cancer cells by 
regulating influx of HCO3
- via NBCn1 and efflux of H+ via NHE1. NBCn1 is the predominant 
means of H+ extrusion from tumour cells when pHi is > 6.6, whereas NHE1 is important 
under more acidic conditions, such as those observed in highly glycolytic cancer cells in a 
hypoxic tumour (42, 84, 85). Since both transport mechanisms are present in cancer cells 
(42, 86), they may work in tandem to facilitate Na+-dependent tumour progression. Increased 
NHE1 activity leads to intracellular alkalinisation (87) and this may be a critical early event in 
oncogene-induced malignant transformation (88). Maintenance of a high pHi by NHE1 
activity is permissive for upregulation of both glycolytic activity and protein synthesis required 
for rapid cell growth and division (1, 89, 90). On the other hand, extracellular acidification 
promotes invasion and suppresses the immune response (91, 92). Thus, inhibition of the 
inward Na+ gradient may provide an effective intervention to manipulate tumour pH for 
therapeutic benefit. 
 
The acidic pH of tumours may also reciprocally regulate Na+ conductance. For example, 
ENaC and ASIC channels are regulated by pHe (58, 59) and the persistent inward Na
+ 
current carried by VGSCs is increased under hypoxia or extracellular acidification (93, 94). 
Similarly, the Na+/Ca2+ exchanger (NCX) is also regulated by pH, with an acidic pHi inhibiting 
forward (Ca2+ efflux/Na+ influx) mode action (95). Moreover, given that the sensitivity of NCX 
 9 
to H+ requires intracellular Na+ (96), it is tempting to speculate that the altered pH and Na+ 
levels in tumours work in tandem to perturb Ca2+ signalling and homeostasis. 
 
Regulation of metabolic activity 
Altered tumour [Na+] leads to changes in glucose metabolism that facilitate cancer 
progression. In a phenomenon first reported by Warburg in the 1920s (97), cancer cells 
exhibit upregulated glycolysis with conversion of glucose to lactic acid despite the presence 
of abundant oxygen (‘aerobic glycolysis’). This shift in metabolism towards a more glycolytic 
phenotype confers numerous survival advantages for cancer cells, including survival within a 
hypoxic tumour core, and is associated with rapid cell proliferation, acidification of the 
tumour microenvironment, metastasis and poor patient outcome (98). In addition to directly 
regulating cancer cell metabolism via the hypoxia sensor HIF-1α, tumour hypoxia may 
indirectly contribute to a highly glycolytic phenotype via elevation of tumour [Na+]. Elevations 
in both tissue and intracellular [Na+] are observed in ischaemic tissue (99), and hypoxia is 
known to increase the persistent inward Na+ current through VGSCs (100, 101). This 
increase in the persistent Na+ current would be expected to elevate [Na+]i in cancer cells 
expressing these channels. Moreover, in hypoxic tumours, upregulation of glycolysis and 
increased extrusion of H+ by NHE would increase [Na+]i (102). 
 
In vitro studies indicate that elevations in [Na+]e can drive a highly glycolytic phenotype via 
the induction of various signalling pathways. For example, early studies revealed that 
glycolytic lactic acid production of HeLa cells increased as [Na+]e increased (103). Elevated 
[Na+]e upregulates the key cancer-associated glycolytic enzymes pyruvate kinase M2, lactate 
dehydrogenase A and hexokinase II, leading to increased glucose consumption and lactate 
production (104). Elevated [Na+]i may influence cancer cell metabolism due to increased 
energy demands from Na+ homeostasis mechanisms. Indeed, Na+/K+ ATPase activity can 
also regulate the expression of glycolytic enzymes, and G-protein GPR35 mutations, which 
increase Na+/K+ ATPase activity, increase the glycolytic rate (105). Conversely, inhibition of 
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the Na+/K+ ATPase reduces expression of the hypoxia sensor HIF-1α, preventing it from 
upregulating glycolysis via increased expression of the glucose transporter GLUT-1 and 
hexokinase (106). 
 
Altered [Na+]i may also directly affect mitochondrial metabolism by facilitating Ca
2+ transport 
between the mitochondria and the cytosol. The mitochondrial Na+/Ca2+ (lithium) exchanger 
(NCLX) regulates mitochondrial Ca2+ content by extruding Ca2+ into the cytosol in exchange 
for Na+ or Li+ (107), and is regulated by the cytoplasmic [Na+]. Thus, NCLX uses Na+ 
transport to fine-tune the mitochondrial [Ca2+], thereby regulating mitochondrial metabolism, 
redox homeostasis and ATP production (108, 109). Inhibition of NCLX induces apoptosis in 
prostate cancer cells (110), suggesting that an elevated [Na+]i in cancer cells might promote 
apoptosis resistance via NCLX. Taken together, these data suggest that elevated tumour 
[Na+] and Na+/K+ ATPase activity contribute to a highly glycolytic cancer cell phenotype, 
which would be expected to promote proliferation, tumour acidification and resistance to 
apoptosis. However, the underlying mechanisms linking tumour [Na+] to cancer metabolism 
remain poorly characterised and require further research. 
 
Nutrient transport 
Amino acids regulate cancer cell signalling and metabolism (111), raising the possibility that 
altered amino acid uptake through Na+-dependent systems might influence cancer 
progression following changes to the transmembrane Na+ gradient. For example, the Na+-
dependent SGLT glucose transporters facilitate glucose uptake into cancer cells, and 
specific blockade of SGLT2 reduces mitochondrial ATP production and cellular proliferation 
and increases tumour necrosis (45, 112). Moreover, the Na+-dependent amino acid 
transporter SLC1A5, which is highly expressed in cancers and is driven by myc expression, 
imports glutamine (among other amino acids), and activates mammalian target of rapamycin 
complex 1 (mTORC1) to facilitate proliferation (113, 114). Many cancers, including triple-
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negative breast cancer, have a “glutamine addiction” since this amino acid is a key carbon 
source for fatty acid production and mitochondrial ATP production (115, 116). Changes to 
the Na+ gradient may therefore regulate nutrient uptake in cancer cells and these 
observations raise the interesting possibility that pharmacologically reducing the inward Na+ 
gradient may impair the ability of cancer cells to import nutrients. 
 
Cell volume regulation 
Na+ salts are the main contributors to the osmolarity of extracellular fluid, and the osmolarity 
of intracellular and extracellular fluids must be balanced to prevent cell shrinkage or swelling. 
The Na+/K+/Cl- cotransporter NKCC1 activity is driven by the inward Na+ gradient and acts to 
regulate cell volume by facilitating the accumulation of intracellular Cl- (117). Solid tumours 
exhibit a high interstitial colloid osmotic pressure (COP) and hydrostatic pressure in the 
interstitial fluid (13) which would be expected to hinder cell expansion. In vitro evidence 
shows that breast cancer cells in spheroids under compression actively extrude Na+ through 
NHE1 to reduce intracellular tonicity, leading to osmosis into the cell to resist compressive 
forces (118). In this circumstance, NHE1 functions in the reverse mode, importing H+ leading 
to intracellular acidification. Thus, by regulating Na+ as well as H+, NHE1 activity must 
balance the cell’s pH and volume regulation needs. In hypotonic conditions, cancer cells 
regulate [Na+]i to protect against volume increase (119). Therefore, tight regulation of Na
+ 
transport is critical for maintaining cell volume in response to changes in COP and 
hydrostatic pressure in the tumour microenvironment. 
 
Effects of Na+ on tumour progression  
 
As a result of its impact on physiological behaviour of cancer and stromal cells, substantial 
experimental evidence supports the role of raised [Na+] in promoting key aspects of tumour 
progression, including proliferation, migration, invasion and inflammation (22, 120-122) 
(Figure 4). 
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Proliferation 
High osmolarity in the tumour microenvironment promotes proliferation via modulation of 
[Na+]i. Because the tumour interstitial fluid COP is higher than in healthy tissues (123, 124), 
and this contributes to a higher osmolarity, inward Na+ current is enhanced in cancer cells. 
For example, high osmolarity increases inward Na+ current through ENaC, which elevates 
[Na+]i, promotes tumour cell proliferation and inhibits apoptosis (121, 125, 126). This 
hyperosmolarity-induced inward current may promote proliferation by triggering brx-
dependent activation of the small GTPase Rac1 thus stimulating the mitogen-activated 
protein kinase (MAPK)/ERK1/2 cascade (127, 128). High [Na+]e has also been shown to 
increase phosphorylation of the salt-inducible serine/threonine kinase SIK3 in breast cancer 
cells, which promotes proliferation via release from G1/S-phase arrest (129). Moreover, 
NKCC1 expression, cell shrinkage and Na+-dependent Cl- accumulation have been 
established as important regulators of the cell cycle and proliferation in cancer cells (48, 117, 
130). On the other hand, moderate hypertonicity has been shown to lead to dormancy (131), 
suggesting that the level of osmotic pressure within tumours, and the cellular response to 
this, may be critical for determining fate. High [Na+]e has also been shown to induce DNA 
breaks and temporary cell cycle arrest (132). However, unlike most cases of DNA damage-
induced cell cycle arrest, these DNA breaks are not repaired during this period, and the DNA 
damage persists when cells adapt to high [NaCl]e and start to proliferate, with implications 
for oncogenesis (133-135). 
 
Migration 
Several Na+ transport systems have been shown to control tumour cell migration. For 
example, NHE1 has been shown to work in concert with aquaporins to allow cancer cells to 
move through confined spaces by taking in water and ions at the leading edge and expelling 
water from the trailing edge. This is achieved partly by concentrating NHE1 and aquaporin 
AQP5 at the leading edge of cells (136). Similarly, ENaC expression is increased at the 
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leading edge of migrating choriocarcinoma cells, promoting their motility (137). In addition, a 
glioma-specific Na+ channel made up of ENaC and ASIC subunits promotes migration and 
cell cycle progression (138). VGSC activity has also been shown to promote acquisition of a 
mesenchymal-like elongate morphology and thus increase migration of cells from a range of 
different types of cancer (139-144). 
 
The Na+ gradient across the plasma membrane is tightly linked to Ca2+ transport by the 
Na+/Ca2+ exchanger (NCX), which is also upregulated in tumour cells (145, 146). NCX 
classically acts to extrude cytosolic Ca2+ following large increases in [Ca2+]i, thereby 
importing Na+ (147). Importantly, small changes to the Na+ gradient across the plasma 
membrane can alter the equilibrium potential for NCX and thereby lead to its operating in 
reverse (Ca2+ entry/Na+ exit) mode (148, 149). NCX reverse mode action has been 
implicated as a key mediator of transforming growth factor β (TGF-β)-induced Ca2+-
dependent migration in hepatocellular and pancreatic cancer cells (150, 151). NCX may thus 
provide a mechanism linking elevations in [Na+]i to protumour Ca
2+ signalling (149, 152). 
Interestingly, NCX inhibition has also been reported to decrease the intracellular 
accumulation of 11C-choline in cancer cells. This has important implications for positron 
emission tomography (PET) imaging, since alterations in tumour Na+ content might 
compromise NCX action and thus lead to poor contrast agent accumulation within tumours 
(153). 
 
Invasion 
A cancer hallmark commonly associated with aberrant Na+ homeostasis is the ability of 
cancer cells to invade into healthy tissues and migrate around the body to form metastases 
(49). Invasion requires proteolytic breakdown of the extracellular matrix by enzymes such as 
matrix metalloproteases and cathepsins. Cathepsins in particular are activated by low pH 
(154) so Na+-dependent tumour acidification may thus facilitate invasion. NHE1 is expressed 
in the invadopodia of migrating breast cancer cells and colocalises with the invadopodial 
 14 
marker cortactin (155). NHE1 activity in the invadopodia leads to local acidification of the 
extracellular compartment, providing the ideal pH conditions at the leading edge of an 
invading cell for digestion of the extracellular matrix (87, 120, 156-159). 
 
VGSCs also promote the invasiveness and metastatic ability of a range of different cancer 
cell types (26, 141, 160, 161) and VGSC expression correlates with lymph node metastasis 
and a poor prognosis in breast cancer patients (54, 160). This appears to rely on the Na+ 
conductance properties of VGSCs, since silencing VGSC expression or specific blockade 
results in decreased invasion in vitro (22, 161) and metastasis in vivo (162, 163). VGSCs 
facilitate an invasive phenotype by inducing transcriptional changes in genes contributing to 
Wnt, MAPK and Ca2+ signalling (161, 164). VGSC activity may also increase cancer cell 
invasiveness through altering pH homeostasis. VGSC-dependent Na+ influx in caveolae 
promotes H+ extrusion by NHE1, thus acidifying the extracellular space and increasing 
cathepsin B protease activity (120, 142, 152). The authors proposed a putative allosteric 
interaction between VGSCs and NHE1 as the mechanism by which this interaction is 
mediated, since Na+ influx would otherwise be expected to reduce the Na+ gradient driving 
H+ export by NHE1 (142). 
 
ASICs are also upregulated in tumour cells where they promote pH-dependent migration and 
invasion (165). For example, ASIC1a increases [Ca2+]i and promotes migration as a result of 
pHe acidification (166) and ASIC2 mediates acidosis-induced invasion and metastasis (56). 
ASIC opening also results in activation of RhoA and induction of the epithelial-mesenchymal 
transition in pancreatic cancer cells (167). Co-expression of NMDA receptors and glutamate 
transporters (vGlut1–3) in glioma, pancreatic and ovarian cancer cells correlates with poor 
prognosis, suggesting an autocrine signalling mechanism that drives disease progression 
(60). Moreover, in vitro invasion and in vivo tumour burden are both decreased following 
treatment with a selective non-competitive NMDA receptor antagonist (60). Although these 
effects were attributed to Ca2+ entry-induced activation of the Ca2+/calmodulin-dependent 
 15 
protein kinase (CaMK) and mitogen-activated protein kinase kinase (MEK)-MAPK pathways, 
it remains to be determined whether elevated Na+ entry via NMDA receptors also contributes 
to their pro-invasive potential. 
 
NKCC1 is also localised to the leading processes of migrating glioma cells, where it 
facilitates invasive behaviour by regulating focal adhesions, Cl- accumulation and cell 
volume (47, 117, 168). The cell shrinkage that results from Na+-linked Cl- accumulation 
allows the invading cell to navigate narrow gaps in the peritumoural space. Interestingly, 
NKCC1 expression in hepatoma cells is upregulated in response to hyperosmolarity (169), 
suggesting that an elevation in tumour [Na+]e could promote an aggressive cell phenotype 
overexpressing NKCC1. These findings implicate NKCC1 as an important mediator of 
invasive potential and suggest that elevated Na+ may exacerbate metastatic behaviour by 
upregulating NKCC1 expression and Na+-linked Cl- accumulation. 
 
Tumour inflammation 
In sites of acute inflammation induced by inoculation with complete Freund adjuvant, BCG, 
or Leishmania, [Na+]e is increased (170, 171), leading to alterations in immune cell function 
(172, 173). The [Na+]e within inflamed solid tumours has not been studied, but it may be 
similarly altered. Chronic inflammation plays a critical role in cancer progression due to the 
abundance of cytokines and chemokines which stimulate proliferation and angiogenesis, and 
the release of reactive oxygen and nitrogen species from inflammatory cells which can 
cause DNA damage (174). Inflamed tissue has an increased extracellular osmolarity (171, 
175, 176), and hyperosmolar conditions (e.g. high [Na+]e) exacerbate inflammation (177, 
178). Hyperosmotic stress is detected by many cell types including epithelial cells where it 
leads to activation of the nuclear factor of activated T-cells (NFAT-5) transcription factor. 
NFAT-5 is responsible for mediating integrin-induced breast cancer cell invasion (122). In 
macrophages, NFAT-5 activation in response to a hyperosmolar extracellular environment 
results in secretion of VEGF-C which stimulates angiogenesis (179). Hyperosmotic stress 
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upregulates production of inflammatory cytokines including interleukin (IL)-1β, IL-6, IL-8 and 
tumour necrosis factor-α (TNF-α) via the transcription factor nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) (171). High Na+ in the microenvironment also provides 
a mitogenic stimulus to macrophages via activation of the p38 MAPK cascade (180). In 
addition, hyperosmolarity prolongs survival of macrophages by reducing production of the 
pro-apoptotic molecules p53 and bax (171). Tumour-associated macrophages (TAMs), 
which promote many aspects of cancer progression (181), may therefore be more prevalent 
in hyperosmotic tumour microenvironments. However, while evidence indicates that high 
[Na+]e stimulates an immune response in the skin via p38/MAPK and NFAT5 signalling and 
classical (M1) macrophage activation (170), studies have also shown that high [Na+]e 
induces peripheral macrophages to switch to an anti-inflammatory M2 (alternative activation) 
phenotype with poor phagocytic capacity, which would be expected to facilitate tumour 
progression rather than inhibit it (182). Based on these data, it appears that the regulation of 
the anti-tumour immune response by Na+ is highly complex and may be tissue-specific 
(183). 
 
Many pro-inflammatory effects of elevated [Na+]e are mediated by the cytokine IL-17. IL-17 is 
produced by CD4+ T-helper 17 (Th17) cells in response to high [Na+]e, downstream of 
NFAT-5 activation (177). IL-17 signalling facilitates tumour development and progression 
(184-186). Thus, IL-17 induction by hyperosmotic stress links high [Na+]e to both tumour cell 
survival and metastasis. Indeed, elevated [Na+]e and IL-17 have been shown to induce 
expression of the promigratory VEGF-A (187). The synergistic proinflammatory effects of 
high [Na+]e and IL-17 can also be mediated by SIK3 to increase arginine metabolism, 
reactive nitrogen species production, CXCL-12 expression and matrix metalloproteinase 
(MMP9) activation (129). Interestingly, the high [Na+]e-induced component of the 
inflammatory response could be blocked by inhibiting Ca2+ influx or by knockdown of the 
store-operated Ca2+ entry (SOCE) regulatory molecules stromal interaction molecule 
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(STIM1) and Orai1, suggesting that these changes are governed by store-operated Ca2+ 
entry (188). These studies show that elevated [Na+]e can drive tumourigenicity via NFAT5, 
NF-κB, SIK3 activation and SOCE mechanisms. 
 
Diagnostic implications 
 
The accumulating body of evidence implicating altered Na+ handling in regulating cancer cell 
behaviour, tumour metabolism, acidosis, growth, inflammation and invasion raises the 
intriguing possibility that the tumour [Na+] may have value as a diagnostic or predictive 
biomarker in response to treatment. For example, measurement of [Na+]i may serve as a 
biomarker for both hypoxia-induced necrosis and cell death in response to successful 
chemotherapy treatments. Earlier detection of treatment response using techniques such as 
23Na MRI (Box 1) may thus facilitate more timely selection of optimal therapies for individual 
patients, thereby improving clinical outcomes (189). 23Na MRI was first applied to 
supratentorial brain tumours in patients (190). Subsequently, this under-represented imaging 
methodology was used to show that the tissue [Na+] is higher in malignant gliomas 
compared to normal brain tissue (4). A similar pattern was observed for breast (9, 191) and 
prostate tumours (25). This elevated tissue [Na+] is present in both tumour tissue and 
oedema. Furthermore, [Na+] is heterogeneous across the peritumoral region, suggesting that 
altered tissue [Na+] may be demonstrating local physiological or biochemical changes within 
the tumour microenvironment (Figure 1) (9). Additionally, relaxation-weighted 23Na-MRI can 
differentiate between brain tumours of grades I-III and grade IV (192). However, while similar 
trends linking tumour grade to [Na+] have been observed in breast and prostate cancers, any 
differences between tumour grades were below the threshold of statistical significance (25, 
193). As such, future clinical studies with larger cohorts are needed to better determine the 
correlation between tumour [Na+] and tumour type and grade. 
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A limitation with these observations using 23Na MRI is that they did not differentiate between 
Na+ located within the intracellular and extracellular compartments. To investigate this, Neto 
et,al. (2018) determined [Na+]i and [Na
+]e in brain tumours (194). This revealed that although 
lesions have higher total [Na+] than the normal appearing white matter, the extracellular 
volume fraction is also consistently elevated, whereas the apparent [Na+]i is lower than in 
white matter. This would imply that that increased extracellular volume may underlie the 
majority of the elevated tissue [Na+]. However, relaxation-weighted 23Na MRI has shown that 
[Na+]i is elevated in glioblastomas and cerebral metastases (192) and is supported by in vitro 
data (22, 26). This observation of elevated [Na+]i has since been supported by additional 
studies in breast and prostate tumours using fluid suppression by inversion recovery and 
diffusion-weighted MRI approaches (25, 193, 195). Taken together, these studies suggest 
that both increases in extracellular volume fraction and [Na+]i can contribute to elevated total 
tissue [Na+] in cancer, although the relative contributions of these two compartments may 
vary between tumour type and location. 
 
23Na MRI may have the potential to complement standard of care radiological imaging 
approaches including positron emission tomography (PET). Elevated [Na+]i in brain tumours 
correlates with the proliferation marker MIB-1 (192), raising the possibility that 23Na MRI may 
complement 18F-fluorothymidine positron emission tomography ([18F]FLT-PET) for 
proliferation assessment in CNS tumours (196). In addition, 23Na MRI measurement of total 
tumour [Na+] has been shown to be superior to isocitrate dehydrogenase (IDH) mutation 
status in predicting progression-free survival, suggesting that tumour [Na+] may be a 
promising tool for non-invasive outcome prediction (197). Furthermore, 23Na MRI may also 
have value for detecting changes in real-time during treatment as a potential early biomarker 
for therapy assessment (198). However, it must be noted that [Na+] is likely to change 
following initiation of treatment as a result of physiological changes in the tumour and so the 
relationship between [Na+] and therapy response may be complex. For example, in a 
preclinical mouse xenograft model of prostate cancer, [Na+]i increased within 24 h of 
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initiation of chemotherapy treatment (24), whereas in a rat glioma model, [Na+]i was 
significantly reduced 5 days after onset of chemotherapy (199). In broad agreement with the 
latter, total tumour [Na+] is reduced in breast cancer patients responding to neoadjuvant 
chemotherapy (189, 200). However, the heterogeneity of [Na+] within the tumour following 
therapy is likely to be critical. For example, chemotherapy-induced cellular necrosis would be 
expected to increase the extracellular volume fraction, likely underpinning the early increase 
in total tissue [Na+] observed in preclinical tumour models following onset of therapy (201-
203). Clearly, it is necessary to evaluate changes in both [Na+]i and [Na
+]e in response to 
therapeutic intervention in order to evaluate predictive value of Na+ in the clinical setting. 
Whether MRI can do this remains to be explored across both preclinical and clinical theatres. 
 
Therapeutic potential of manipulating Na+ levels 
 
Directly or indirectly manipulating tumour Na+ levels, for example by using pharmacological 
tools to manipulate transporter activity, may present novel treatment options to complement 
existing therapeutics. Indeed, numerous studies are presently ongoing to evaluate targeting 
tumour [Na+] (Table 2). Given that tumour acidification can induce drug resistance (1, 81, 
204) and Na+ and pH are very closely linked, pharmacological modification of tumour [Na+] 
may be a useful adjunct to other chemotherapeutics. For example, the ENaC/NHE1 blocker 
amiloride strongly synergises with doxorubicin to induce apoptosis and reduce glycolysis in 
osteosarcoma cells (205). On the other hand, Na+/K+ ATPase activity is increased in 
hepatocarcinoma cells upon development of resistance to chemotherapeutics (206). 
Similarly, high [Na+]e increases expression of the multi-drug resistance protein P-
glycoprotein in breast cancer cells in a Ca2+-dependent manner (188). In addition, elevated 
[Na+]i-mediated acidification of the tumour microenvironment may help cancer cells to evade 
immune surveillance. Acidotic conditions correlate with low leukocyte counts (207) and 
decrease cytotoxicity of natural killer (NK) cells (208) and cytotoxic T-lymphocytes (209). 
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Thus, tumour [Na+]e may modulate response to existing chemotherapeutics and emerging 
immunotherapeutics via pH- and non pH-dependent mechanisms. 
 
Extracellular [Na+] in tumours would be expected to follow serum [Na+] and indeed, 
hypertonic interstitial fluid accumulates in the skin of rats fed on a high salt diet (179). Since 
elevated tumour [Na+]e may promote tumour progression, serum [Na
+] is likely critical in 
cancer patients. Hypernatremia, which has a high mortality rate, is an uncommon side effect 
of some chemotherapy regimes (210). Significantly, NaHCO3 infusions, currently under test 
as a treatment to increase extracellular pH in cancer (Table 2), should be considered in the 
light of these findings. The risks associated with elevating [Na+]e (211) will need to be 
balanced against any advantages of reducing tumour acidity. Recently TRIS-base has been 
identified as a well-tolerated and effective anti-metastatic oral pH buffer in mice which does 
not require a counter-ion and would therefore not be expected raise [Na+]e (212). 
 
Several studies have examined whether normalising tumour [Na+] might be a useful 
treatment strategy. The use of VGSC inhibitors to prevent cancer growth and metastasis has 
been investigated in several preclinical studies (162, 213-215), and is currently the subject of 
several ongoing clinical trials (Table 2). In support of this, in retrospective observational 
studies, VGSC-inhibiting tricyclic antidepressants and antiepileptic medications have been 
shown to associate with reduced incidence of several common cancers including lung and 
colorectal cancer and glioma (216, 217). On the other hand, antiepileptic medications 
associate with increased mortality in breast, bowel and prostate cancer patients, although 
this may be a result of confounding by indication (218, 219). Significant improvements in 
cancer outcomes have been associated with local anaesthetic drugs such as lidocaine (220) 
and the anti-epileptic drug valproate in combination with doxorubicin (221) or a 
topoisomerase inhibitor (222); however the benefits may be attributed to other mechanisms 
in addition to VGSC inhibition. For example, regional anaesthesia reduces the need for 
general anaesthetic drugs and opioids, which have various deleterious effects on immunity 
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(223). The local anaesthetic lidocaine stimulates natural killer cell cytolytic activity (224) and 
several local anaesthetics inhibit src activity independently of VGSC blockade (225). As well 
as inhibiting VGSCs, valproic acid acts as a histone deacetylase inhibitor, and this action is 
commonly considered responsible for its anti-cancer properties (226). VGSCs are also 
inhibited by omega 3 fatty acids, which may explain some of the beneficial effects shown by 
these molecules in the diet of cancer patients (227, 228). A low Na+ diet, which reduces the 
risk of hypertension, has been hypothesised to be beneficial in preventing cancer (229). 
While speculative, this is supported by data from a meta-analysis of prospective studies 
examining habitual salt intake (230). However, a low Na+ diet may be difficult to achieve as a 
therapeutic intervention in the clinic as factors such as patient nutrition and blood pressure 
are already very difficult to control in patients with advanced disease. Furthermore, a 
complicating factor when considering VGSC inhibition as a therapeutic strategy is that these 
channels may also play a role in regulating immune cell function (231). 
 
The reverse approach has also been considered: given that apoptosis is initiated by a large 
influx of Na+ into cells (232), attempts have been made to replicate this mechanism to kill 
cancer cells. Viral vector delivery of a constitutively open ASIC channel into culture glioma 
cells caused Na+ entry and cell death (233). However, viral delivery of Na+ channels would 
need to be precisely targeted to neoplastic cells in order for this method to be of use. In a 
different study, targeted osmotic lysis of VGSC-expressing tumours in mice was 
demonstrated by systemic administration of the Na+/K+ ATPase-inhibiting cardiac glycoside 
ouabain in conjunction with electrical pulses to open VGSCs, leading to cytotoxic influx of 
Na+ into tumour cells (234). Blocking the Na+ efflux activity of Na+/K+ ATPase with cardiac 
glycosides has the added advantage of decreasing inflammation and increasing specific 
anti-tumour immunity (235). A retrospective study showed improved survival in cancer 
patients that were being prescribed cardiac glycosides despite these patients having cardiac 
conditions (236). This has led to the development of several clinical trials examining the 
effect of adding the cardiac glycosides to various chemotherapy protocols (Table 2). 
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Conclusion 
 
Na+ homeostasis is disrupted in cancer, leading to accumulation of Na+ in solid tumours. At 
the cellular level, Na+ transport is linked to pH and Ca2+ regulation and it alters plasma 
membrane potential, metabolism and proliferation. At the tissue level, high [Na+]i aids 
proliferation, migration and invasion of cancer cells and high [Na+]e induces an inflammatory 
microenvironment which promotes tumour progression. Systemic changes in [Na+] affect 
blood pressure and immune function, together with secretion of pro-angiogenic mediators. 
Given that Na+ is the predominant extracellular cation and its distribution can be affected by 
diet and many drugs in common use, it is imperative that we further improve understanding 
of how Na+ regulation affects cancer progression. There is plenty of evidence that by doing 
so, we will uncover new modes of cancer detection and monitoring, e.g. through use of 23Na-
MRI, and may also improve cancer treatment via pharmacological and dietary modulation of 
Na+ homeostasis. 
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Table 1. Na+ transport mechanisms with altered expression in cancer. 
Transporter Subtype Cancer Change Effects References 
Na+/K+ 
ATPase 
α3 subunit Liver, gastric ↑ ↑ proliferation 
↑ migration 
↑ invasion 
↓ apoptosis 
(206, 237) 
ENaC αENaC, γENaC Glioblastoma, 
HCC, 
melanoma, 
placenta 
 
↑ ↑ migration 
↑ proliferation 
(121, 137, 238, 239) 
 
ASIC ASIC1, ASIC1a, 
ASIC2, ASIC2a, 
ASIC3 
Liver, 
glioblastoma, 
PDAC, 
colorectal, 
adenoid 
↑ ↑ invasion  
↑ migration 
↑ EMT 
(56, 165, 167, 238, 240) 
VGSC Nav1.2, Nav1.4, 
Nav1.5, Nav1.6, 
Nav1.7 
NSCLC, 
prostate, 
cervical, 
colorectal, 
breast, 
ovarian 
↑ ↑ invasion 
↑ migration 
  
(26, 140, 144, 160, 161, 
241-243) 
NKCC NKCC1 HCC, 
glioblastoma, 
NSCLC 
↑ 
 
↑ invasion 
↑ migration 
↑ proliferation 
 
(47, 244, 245) 
NMDA-R NMDAR2B Glioblastoma 
NSCLC 
ESCC 
gastric 
colorectal 
breast 
↓/↑ 
 
↓ proliferation/ 
↑ proliferation 
 
(246) 
Na+/H+ 
Exchanger 
NHE1 Glioma, 
HNSCC, 
breast, HCC, 
cervical 
↑ ↑ acid 
extrusion 
↑ invasion 
(247-250) 
Na+/HCO3- 
transporter 
NBCn1  Breast ↑ ↑ acid 
extrusion 
(42, 251, 252) 
Na+/glucose 
cotransporter 
SGLT2 Breast ↑ ↑ glucose 
uptake? 
(46) 
Amino acid 
transporters 
SLC1a5/ASCT2  NSCLC, 
glioblastoma, 
eye, kidney, 
liver, lymph 
node, breast, 
muscle, 
placenta, 
skin, gastric, 
colorectal 
↑ ↑ amino 
acid/glutamine 
metabolism 
(253-257) 
 
SLC6A14 Cervical, 
colon, PDAC, 
breast 
↑ ↑ amino acid 
uptake? 
(114, 258, 259) 
 SLC38a3/SNAT3 
 
Glioma ↑ ↑ amino acid 
uptake? 
(260) 
  
SLC38a1/SNAT1 HCC, bile 
duct 
↑ ↑ growth 
↑ survival 
(261, 262) 
NCX  Kidney ↓ ↓ EMT (263) 
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Abbreviations: ENaC, epithelial Na+ channel; VGSC, voltage-gated Na+ channel; NKCC, 
Na+/K+/2Cl- co-transporter; NMDA-R, N-methyl D-aspartate receptor; NCX, sodium calcium 
exchanger; HCC, hepatocellular carcinoma; HNSCC, head and neck squamous cell 
carcinoma; ESCC, oesophageal squamous cell carcinoma; NSCLC, non-small cell lung 
cancer; PDAC, pancreatic ductal adenocarcinoma, EMT, epithelial-mesenchymal transition. 
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Table 2. Na+-regulating mechanisms as potential therapeutic targets1. 
Transporter Compound Category Cancer 
types 
Highest 
phase 
Clinical trial NCT numbers 
and references 
ENaC Amiloride ENaC inhibitor Solid 
tumours 
Preclinical (264) 
 
NHE1 Cariporide NHE1 inhibitor NA Phase III 
(stopped) 
(265) 
 
VGSC Lidocaine VGSC blocker, 
local 
anaesthetic 
Breast, 
colorectal 
Phase III NCT01916317, 
NCT02786329, 
NCT01841294, 
NCT02839668, 
NCT02647385, (266) 
 Ropivacaine VGSC blocker, 
local 
anaesthetic 
Abdominal/t
horacic 
NA NCT03134430 
 Bupivacaine VGSC blocker, 
local 
anaesthetic 
Breast, 
colon 
Phase III NCT00938171, (267) 
 Valproate VGSC blocker, 
HDAC 
inhibitor, 
antiepileptic 
HNSCC, 
cervical, 
melanoma, 
mesothelio
ma, 
bladder, 
thyroid, 
NSCLC 
Phase III NCT01695122, 
NCT01738815, 
(222, 268-270) 
 Phenytoin VGSC blocker, 
antiepileptic 
Breast Preclinical (213) 
 Ranolazine VGSC blocker, 
antianginal 
Breast Preclinical (162) 
Na+/K+ ATPase Digoxin Cardiac 
glycoside, 
Na+/K+ 
ATPase 
inhibitor 
Prostate, 
breast, 
melanoma, 
acute 
myeloid 
leukaemia/
myelodyspa
stic 
syndromes, 
HNSCC 
Phase II NCT02138292, 
NCT03113071, 
NCT02906800, 
NCT01763931, 
NCT01887288, (221, 271) 
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 Ouabain Cardiac 
glycoside, 
Na+/K+ 
ATPase 
inhibitor 
Breast Preclinical (234) 
NKCC Bumetanide NKCC1 
inhibitor 
HCC Preclinical (244) 
NMDA-R Memantine & 
MK-801 
NMDA-R 
blocker 
Breast Preclinical (272) 
NCX KB-R7943 NCX reverse 
mode inhibitor 
Prostate Preclinical (273) 
SGLT2 Empagliflozin 
and others 
SGLT2 
inhibitors 
Urinary 
tract 
Observati
onal 
NCT03464045 
N/A NaHCO3 Neutral pH 
buffer 
Any Phase I NCT02531919 
1ENaC, epithelial Na+ channel; VGSC, voltage-gated Na+ channel; NKCC, Na+/K+/2Cl- co-
transporter; NMDA-R, N-methyl D-aspartate receptor; NCX, sodium calcium exchanger; 
HDAC, histone deacetylase; HCC, hepatocellular carcinoma; HNSCC, head and neck 
squamous cell carcinoma; NSCLC, non-small cell lung cancer; EMT, epithelial-mesenchymal 
transition. 
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Box 1: Development of 23Na MRI 
 
23Na MRI is non-invasive and presents a unique mechanism for measuring Na+ in tissue. 
23Na MRI does not disturb the tissue state, unlike Na+ measurements that require physical 
tissue sampling. Na+ is endogenous to human tissue, which enables imaging without 
external contrast. 23Na MRI can differentiate intracellular Na+ from total tissue Na+. The non-
invasive quantification of cancer Na+ content with MRI has the potential to provide a large 
amount of information on tissue microstructure and function that could improve our 
understanding of the changes occurring in this disease both early on in formation and in 
response to therapy. 23Na MRI is currently primarily used for research due to the non-
standard hardware necessary to enable Na+ signal acquisition. The signal from 23Na MRI is 
much lower than the signal in conventionally used H+ MRI for several reasons: Na+ has a 
lower abundance in the human body compared to H+, which proportionally reduces the 
available magnetization and therefore signal-to-noise; the gyromagnetic ratio of Na+ (11.26 
MHz/Tesla) is 4 times smaller than that of H+, which results in 25 % fewer 23Na spins being 
magnetized; and Na+ has a spin of 3/2, which causes electrostatic field sensitivity and fast 
T2* signal decay. Thus, the total Na+ signal available on MRI in human tissue is only about 
1/22,000th the size of the H+ signal (274). High static magnetic fields are commonly used 
with Na+ imaging to improve the signal to noise ratio. Moving to higher MRI field strengths, 
such as 7 Tesla, further increases the signal-to-noise, enabling higher spatial resolutions in 
faster acquisition times, which improves the probing of the tumour Na+ microenvironment 
(193). 
 
Interest in performing 23Na MRI dates back as far as the 1980s. It was postulated that 23Na 
MRI would allow for superior contrast in distinguishing features of brain tumours such as 
oedema, necrosis and non-necrotic tumour, compared to conventional proton spin density 
imaging (275). Initial studies focused on healthy volunteers and animal models of stroke and 
myocardial infarction (275, 276), followed by the first images of brain tumour patients (277). 
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A set of publications followed (278-280) after which the focus turned to spectroscopic and 
animal model studies and small investigative human studies (190, 281). It was shown that 
23Na MRI reliably revealed brain tumour lesions, albeit no correlation to histology or grading 
(190). Imaging developments in pulse sequence design and quantification methods were 
subsequently made to overcome shortcomings of previous studies, namely to increase 
spatial resolution and to capture the Na+ signal in its entirety by using ultra-short echo time 
imaging (282-284). Further detailed 23Na MRI studies followed in human brain and breast 
tumours (4, 9, 285). More recent advances in sodium imaging have shown that 23Na MRI 
can both predict IDH status (197) and show early response to pre-clinical therapeutic 
interventions (198). Furthermore, relaxation-weighted 23Na MRI has now been shown to 
differentiate between brain tumours of grades I-III and grade IV when spin-weighted 23Na 
MRI was unable to do so (286).  
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Figure legends 
 
Figure 1. Accumulation of Na+ in tumours. Converse to the reported decrease in pO2 and 
pH, many tumours (such as breast cancer) exhibit elevated [Na+] (9). This elevated tumour 
[Na+] may be due to increases in the extracellular volume fraction relative to the intracellular 
volume fraction, or due to increases in the [Na+] concentration within either compartment. 
Moreover, tumour [Na+] is likely influenced by the heterogeneity of the tumour 
microenvironment. Factors that could increase the extracellular volume fraction (interstitial 
volume) include increases in colloidal and interstitial pressure (13) due to vasculature 
permeabilisation, blood plasma protein release and the formation of fibrin (11, 12), and 
cancer cell death as a result of targeted chemotherapy or poor vascularisation within the 
necrotic tumour core. Moreover, Na+ binding to protein sequestered within the desmoplastic 
tumour microenvironment (e.g. glycosaminoglycans) could contribute to an increase in the 
extracellular Na+ content (287). Alternatively, the increased cellularity observed within poorly 
vascularised tumours (193) suggests that increases in intracellular volume fraction can 
contribute to elevated tumour [Na+]; indeed, [Na+]i has been reported to be elevated in 
cultured cancer cells (20, 22, 23), potentially due to altered transporter expression (Table 1). 
 
Figure 2. Cellular Na+ import and export mechanisms. Cells exhibit a diverse repertoire of 
Na+ channels and transporters, many of which exhibit altered expression in cancer (Table 1) 
and are being explored as potential therapeutic targets (Table 2). The activity and 
conductance of these channels is regulated by [Na+]i, [Na
+]e, membrane potential and 
auxiliary regulatory proteins. Channels that facilitate Na+ influx include voltage gated Na+ 
channels (VGSC), epithelial Na+ channels (ENaC), acid-sensing channels (ASIC), 
glutamate-activated N-methyl-D-aspartate receptors (NMDA), ATP-activated P2X 
purinoceptor 7 (P2X7) and the G protein-coupled Na
+ leak channel, non-selective (NALCN). 
The inward Na+ gradient and a hyperpolarised membrane potential are maintained by the 
ATP-driven Na+/K+ ATPase. Na+ influx is also linked to the transport of numerous other ions 
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and substrates, namely H+ efflux (Na+/H+ exchanger 1, NHE1), Cl- and K+ influx (Na+-K+-Cl- 
cotransporter, NKCC), cytosolic and mitochondrial Ca2+ efflux (Na+/Ca2+ exchanger, NCX and 
mitochondrial Na+-Ca2+(Li+) exchanger, NCLX, respectively) glucose uptake (sodium-glucose 
linked transporter, SGLT) and amino acid (AA) uptake. Na+/H+ exchangers (NHE) are also 
present on both mitochondria and lysosomes, the latter of which achieve Na+ efflux into the 
cytosol via two-pore channels (TPC) and transient receptor potential mucolipin (TRPML) 
channels. 
 
Figure 3. Physiological consequences of Na+ accumulation within tumours. Dashed arrows 
indicate putative mechanisms which remain to be fully characterised. Red arrows indicate 
denote movement/conversion of metabolites. A: Elevated [Na+] is linked to alterations in 
tumour metabolism and pH regulation. Elevations in [Na+]i activate the Na
+/K+ ATPase, 
thereby raising ATP demand and driving a high glycolytic rate (34). To maintain a high pHi, 
the resulting H+ is rapidly extruded by NHE, which is driven by the inward Na+ gradient. 
Increased [Na+]i could also facilitate depletion of mitochondrial Ca
2+ ([Ca2+]m) via NCLX, 
thereby altering mitochondrial metabolism. Conversely, changes to the Na+ gradient across 
the plasma membrane will likely alter the driving force for transporters importing key 
metabolic substrates such as glutamine (SLC1A5) and glucose (SGLT), thereby influencing 
anabolic and anapleurotic processes. B: Elevated tumour Na+ and membrane potential (Vm). 
Vm is generated by the electrogenic Na
+/K+ ATPase; Na+ influx via VGSC/ENaC/ASICs 
results in a depolarised membrane potential (Vm) in cancer cells. A depolarised Vm can lead 
to the activation of proliferative signalling cascades (such as KRas), cytoskeletal 
reorganisation facilitating migration, and accelerates the cell cycle. Conversely, most healthy 
differentiated cells exhibit a more hyperpolarised Vm that tightly controls cell cycle 
progression. C: Cell volume regulation by Na+-linked transport mechanisms. Elevations in 
tumour [Na+] are linked to changes in cell volume regulation. NKCC sequentially facilitates 
the accumulation of intracellular Cl-, H2O uptake (aquaporins, AQP, and osmosis) and cell 
swelling (288). Conversely, K+-Cl– cotransporters (KCC) mediate Cl- efflux, promoting H2O 
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exit from the cell (289). NHE1 activity results in a net osmotic gain due to Na+ influx; the 
osmolar contribution of intracellular H+ ions is compensated due to the dissociation of 
intracellular buffers. The resulting increase in pHi and [HCO3
- ]i  drives Cl
- import via anion 
exchangers (AE), leading to H2O uptake and cell swelling (290). NHE1 can also operate to in 
reverse mode to resist compressive forces (118). 
 
Figure 4. Effect of elevated Na+ on cancer progression and the tumour microenvironment. 
Dashed arrows indicate putative mechanisms which remain to be fully characterised. A: 
Elevated tumour Na+ and migration/invasion. VGSCs have been correlated with activation of 
a proinvasive gene transcription network upregulating Wnt, MAPK and Ca2+ signalling (161, 
164). NHE1 localises to the leading edge of invading cells (136); VGSC colocalisation with 
NHE1 within cavaeolae leads to activation of NHE1, acidification of the extracellular 
environment and digestion of the extracellular matrix by cathepsins and matrix 
metalloproteinases (120, 142, 152). Interestingly, the β subunit of VGSCs acts as an 
adhesion molecule that interacts with the extracellular matrix to regulate migration and 
invasion (291). Extracellular acidification can also activate ASIC and ENaC channels (58, 
59), leading to further increases in [Na+]i. Na
+-linked Ca2+ influx via reverse-mode NCX 
action has been linked to cancer cell motility via Ca2+ signalling-activated TGF-β signalling 
(151). NKCC regulates cell swelling required for migratory behaviour by facilitating [Cl-]i 
accumulation and H2O uptake via osmosis and aquaporins (288). NKCC also acts as a 
scaffold for cofilin within invadopodia, which facilitates cytoskeletal remodelling (292). B: 
Elevated [Na+]e and cancer cell proliferation. The inward Na
+ gradient drives the uptake of 
anabolic substrates such as glucose and glutamine (SGLT and SLC1A5), respectively (44-
46); altered tumour [Na+] might regulate the uptake of these substrates. Via 
glycolysis/pentose phosphate pathway (PPP) and glutaminolysis, glucose and glutamine are 
utilised as substrates for redox homeostasis, biosynthesis, and cell proliferation (i.e. 
reducing equivalents, nucleotides, and fatty acids) (293). SLC1A5 also regulates mTORC1, 
a key regulator of protein translation and cell growth (254). Moreover, salt inducible kinase 3 
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is activated by elevated [Na+]e , promoting G1/S phase transition (129), and [Cl
-] 
accumulation due to upregulated NKCC activity can promote cell cycle progression (48, 117, 
130). Elevated [Na+]e leads to DNA breaks with significant implications for oncogenic 
mutations/tumour suppressor silencing (132), and a high osmolality and VGSC activity also 
activates the MAPK signalling cascade, potentially via Rac1 activation (127, 128). C: 
Elevated Na+ and osmolality drives inflammation in the tumour microenvironment. Increased 
[Na+]e and osmolality promote proliferative and antiapoptotic signalling in tumour associated 
macrophages (171) and by increasing the production of proinflammatory cytokines by local 
endothelial cells and Th-17 helper cells (177). Together these factors also promote the 
further recruitment of proinflammatory immune cells (171). These factors lead to extracellular 
matrix breakdown, neovascularisation and tumour remodelling, thereby promoting tumour 
progression and metastasis (129, 179, 187, 294). 
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